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Review
Maintenance antipsychotic treatment
versus discontinuation strategies
following remission from first episode
psychosis: systematic review
Andrew Thompson, Catherine Winsper, Steven Marwaha, Jon Haynes, Mario Alvarez-Jimenez,
Sarah Hetrick, Alba Realpe, Laura Vail, Sarah Dawson and Sarah A. Sullivan
Background
Understanding the relative risks of maintenance treatment
versus discontinuation of antipsychotics following remission in
first episode psychosis (FEP) is an important area of practice.
Method
A systematic review and meta-analysis. Prospective experi-
mental studies including a parallel control group were identified
to compare maintenance antipsychotic treatment with total
discontinuation or medication discontinuation strategies fol-
lowing remission in FEP.
Results
Seven studies were included. Relapse rates were higher in the
discontinuation group (53%; 95% CIs: 39%, 68%; N = 290) com-
pared with maintenance treatment group (19%; 95% CIs: 0.05%,
37%; N = 230). In subgroup analyses, risk difference of relapse
was lower in studies with a longer follow-up period, a targeted
discontinuation strategy, a higher relapse threshold, a larger
sample size, and samples with patients excluded for drug or
alcohol dependency. Insufficient studies included psychosocial
functioning outcomes for a meta-analysis.
Conclusions
There is a higher risk of relapse for those who undergo total or
targeted discontinuation strategies compared with maintenance
antipsychotics in FEP samples. The effect size is moderate and
the risk difference is lower in trials of targeted discontinuation
strategies.
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Antipsychotic medication in early psychosis
Since early intervention services became established for psychosis in
the 1990s, there has been particular research interest in the
treatment of first episode psychosis (FEP). Studies indicate that
when antipsychotic medication is part of the treatment approach,
85–90% of FEP patients will experience symptom remission and
50% of patients will achieve functional recovery by 1 year.1
Nevertheless, longitudinal studies demonstrate that relapse follow-
ing remission in FEP is common.2 Relapse has considerable negative
consequences including functional disability and financial burden.3
Additionally, it may lead to biological alterations, increasing the risk
of future treatment refractoriness.4,5 The majority of current guide-
lines that consider FEP recommend continuing antipsychotic medi-
cation for a period of time following remission in FEP to prevent
relapse, e.g. the Australian Clinical Guidelines for Early Psychosis
states that antipsychotic medication may be continued for
12 months or more and the National Institute for Health and
Care Excellence guideline, Psychosis and Schizophrenia in Adults:
Treatment and Management, states ‘Inform the service user that
there is a high risk of relapse if they stop medication in the next
1–2 years’.6,7 The studies on which these guidelines are based
often pre-date early intervention teams (who deliver a wide range
of psychosocial interventions post-remission, including specific
relapse prevention programmes) and commonly compared strict
placebo regimes with maintenance. Recent trials have considered
alternative discontinuation strategies, such as graded reductions
and intermittent treatment strategies if breakthrough symptoms
occur, which may show different outcomes.8,9 These trials may
represent more common practice than the trials where the discon-
tinuation arm receives only placebo and essentially stops medica-
tion. In fact, it is now considered ethically challenging not have a
protocol that includes ‘rescue’ medication in a contemporary dis-
continuation trial.8 One recent discontinuation trial has suggested
a worse long-term functional outcome in those who continue medi-
cation as opposed to a graded reduction group.8 However, these
trials are clearly different from the previous placebo-controlled
trials and as such have inherent biases, especially if clinicians are
not blinded to study group. Possibly influenced by these new
trials and their paradoxical findings, as well as other concerns
such as long-term metabolic side effects of antipsychotics and
long-term use being associated with the potential loss of grey and
white matter;10 some clinicians’ views on medication discontinu-
ation following relapse during FEP appear to diverge from current
guidelines.11 It is also clear that patients commonly stop or wish
to stop medication following remission, and clinicians are com-
monly asked explicitly about relapse risk.11,12
Current literature
To date, there are two systematic reviews relating to FEP patients
that specifically examine discontinuation versus maintenance
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medication trials. Zipursky et al13 compared the outcomes of non-
affective FEP patients who remained on medication following
remission with those who discontinued their medication. Six
studies were identified, four of which were randomised controlled
trials. Symptom recurrence rates (not the more commonly reported
relapse rates) were particularly high in those who discontinued
medication, with a 1-year weighted mean recurrence rate of 77%
in discontinuation groups v. 3% in the maintenance groups.13 In
a subgroup analysis of their Cochrane review on discontinuation
versus maintenance studies in patients with schizophrenia, Leucht
et al14,15 reported a smaller difference with regard to relapse (not
recurrence) in first episode schizophrenia patients. They reported
that relapse rates at 7–12 months were lower for patients continuing
medication compared with those receiving placebo (maintenance
26% v. placebo 61%; risk ratio 0.47; 95% CIs 0.38–0.58), similar to
the rate for multiple episode patients (27 v. 65%). De Hert et al
(2015)16 reported that relapse rates were consistently higher in
first episode patients who had received either placebo or intermit-
tent treatment versus placebo in their study of schizophrenia
patients, but do not specifically quote overall rates or a rate differ-
ence. Similarly, a recent review by Karson et al (2016)17 includes
all FEP patients but contains both randomised and non-randomised
studies and does not perform a meta-analysis of relapse rates.
However, the results from these reviews, which clearly
favour medication continuation, have not resolved the debate among
researchers and clinicians regarding discontinuation approaches.11,18,19
This may be because there are unanswered questions from these
reviews. First, it is not clear whether relapse rates following discontinu-
ation are similar across the broader FEP population (which include
both affective and non-affective psychosis). This is important because
the majority of early intervention services do not only treat patients
who have a schizophrenia spectrum diagnosis.20 Second, extant
reviews only include studies comparing maintenance medication to
completemedication discontinuation. Inmost clinical services, patients
more commonly reduce their medication slowly over many months
(because abrupt withdrawal may potentially precipitate relapse21) or
opt for strategies that include rescue medication or intermittent treat-
ment if possible prodromal symptoms of relapse are identified. For
example, the recent discontinuation trial of Wunderink et al,8,22
which used such an approach, and the trials of Gaebel et al,9,23 which
compare different discontinuation strategies, are not included in
these reviews. Third, the possible influence of additional psychosocial
interventions (which are widespread in early intervention services)
on the prevention of relapse has not been explored in these reviews.
Finally, the differential effects of maintenance versus discontinuation
medication on other important outcomes such as quality of life and
vocational or social functioning, which have been questioned in
recent discontinuation trials,8 have not been explored.
Aims of the study
With these issues inmind, the aims of the current systematic review and
meta-analysis were: (a) to compare relapse (and hospital admission)
rates, using the risk difference, between FEP patients who continued
antipsychotic medication with those who had a specified medication
discontinuation strategy; (b) to test whether study factors likely to
affect relapse rates, such as relapse threshold and type of discontinuation
strategy, explain any heterogeneity in risk difference estimates; and (c)
to examine differences in psychosocial outcomes between groups
receiving medication continuation versus discontinuation strategies.
Method
We used Cochrane Collaboration systematic review methodology to
inform the methods of the review24 and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines25 to inform the reporting (PRISMA checklist included as
SupplementaryTable 3available athttps://doi.org/10.1192/bjo.2018.17).
Databases and search strategy
MEDLINE, Embase, PsycINFO and all Cochrane library biblio-
graphic databases were searched from inception to 13 October
2016. We used MeSH terms and the ‘explode’ facility in the biblio-
graphic databases as well as free text keywords. In addition, we
searched the references of all included studies and relevant
reviews. We contacted experts in the area to enquire about unpub-
lished/grey studies.
TheMeSH terms used were: antipsychotic agents, psychotic dis-
orders, schizophrenia, age of onset, time factors and recurrence. The
keywords in the search were: [early OR recent OR first OR index OR
primary] AND [psychotic OR psychos* OR schizophren* OR
schizoaffective OR schizo affective] AND [antipsychotic* OR anti-
psychotic* OR neuroleptic*] AND [discontinu* OR cessation OR
withdrawal OR stopping OR maintenance] AND [remission OR
recurrence].
Eligibility criteria
The following list details the inclusion criteria used for study
selection:
(a) Study design: randomised controlled trials.
(b) Comparison groups: maintenance (continued) treatment with
antipsychotic medications versus a discontinuation interven-
tion. This could include strategies to discontinue antipsychotic
medication completely or an intermittent treatment strategy
approach (treating breakthrough or prodromal symptoms of
relapse), so long as the majority of the sample discontinued
their medication. We included those with and without an
active or additional psychosocial component to the discontinu-
ation, e.g. a relapse prevention strategy.
(c) Participants: at least 75% of patients were defined as having a
first episode of a psychotic disorder, or first episode of schizo-
phrenia or being within 3 years of the first episode of a psych-
otic disorder.
(d) A clear definition and duration of remission of psychotic symp-
toms. The participants were found to meet this definition
before participation in the study.
(e) Psychotic relapse rates reported with a minimum follow-up
period of 6 months.
Studies were excluded if:
(a) they were non-English language papers (where no translation
was available);
(b) the studies sampled people with organic disorders;
(c) they did not include a parallel control group;
(d) less than 50% of the patients in the discontinuation group were
able to fully discontinue medication.
Abstract screening for eligibility
One author (A.R.) screened all titles and abstracts to identify poten-
tially relevant articles for full-text retrieval. Two authors (A.R. and
L.V.) independently assessed whether these full-text articles met
the inclusion/exclusion criteria. A third researcher (A.T.) resolved
any disagreements by consensus.
Data extraction
Data extraction was conducted independently by two researchers
(A.R. and L.V.). Disagreements were resolved through discussion
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with a third researcher (A.T.). We recorded the following para-
meters for each study: setting, demographics, inclusion and exclu-
sion criteria of participants, criteria used to define remission and
relapse, number of participants in the maintenance and discontinu-
ation group, the type and exact nature of discontinuation strategy,
information about any other active treatment components, raw
dichotomous and/or Kaplan–Meier rates of psychosis relapse (and
admission to hospital) at follow-up time points and study end, func-
tioning ratings at follow-up time points and study end, and medica-
tion adherence ratings.
Quality assessment
Three authors (A.R., S.A.S. and J.H.) conducted a quality assessment
based on the Cochrane Collaboration risk of bias tool.24 Each entry
was assigned a judgement of ‘low risk,’ ‘high risk’ or ‘unclear risk’.
Disagreements between raters were resolved by consensus by a
fourth researcher (A.T.). We summed risk of bias scores (i.e. low
is 0, unclear or high is 1) for each bias judgement (e.g. allocation
concealment) to calculate a total risk of bias score (out of 9) for
each study. We categorised studies into low (score of 0–6 = 0) v.
high (score ≥7 = 1) risk of bias for inclusion in the sub-analyses
and meta-regression.26
Outcome parameters for meta-analysis
Our primary outcome was relapse, variously described in the
studies (see Table 1). Most studies reported raw relapse rates,
some studies reported relapse rates derived from survival curves
and some studies reported both. Kaplan–Meier estimates may
derive slightly higher relapse rates than raw figures30,32 as
Kaplan–Meier calculations exclude censored data (i.e. those who
have left the trial). In contrast, raw figures are based on the propor-
tion of all participants entering the trial.33 Nevertheless, previous
meta-analyses have combined the raw figures and those based on
Kaplan–Meier estimates32 and this was the approach taken in this
study. However, as a sensitivity analysis, we examined whether
relapse rate calculation (i.e. raw proportion versus Kaplan–Meier
proportion) had an impact on pooled risk difference. Our secondary
outcome was hospital admission.
Narrative synthesis
We narratively combined findings on psychosocial outcomes (i.e.
quality of life/subjective well-being, social functioning and employ-
ment) because results presented in the studies were not suitable for
quantitative synthesis (i.e. the data could not be combined or there
were insufficient studies in respective domains of interest).
Statistical analyses
Meta-analysis
Analyses were conducted in Stata version 13. We combined
outcome data from all eligible studies, using the risk difference
and s.e. We selected the risk difference as the most appropriate
effect size34 because some studies lacked observed events in the
control arm of the trial.27,29 The risk difference and s.e. were calcu-
lated using equations described in Leucht et al.32 Pooled risk differ-
ences for relapse (and hospital admission) were computed across
studies using the metan command. A random effects model was
chosen a priori as we were using real world data, which is likely
to have variable population parameters.35 Heterogeneity among
studies was assessed with the I2 statistic (reported with a P-value).
We also calculated pooled relapse rates using the metaprop
command to give an indication of the actual relapse rates in both
groups. Althoughmetaprop results will vary slightly from those pro-
duced by the metan command (due to extreme outcome
proportions in some of the included studies), the Freeman–Tukey
double arcsine transformation ensures that all CIs are at admissible
rates and that all studies are retained in the analysis.36 This means
that that the two analyses may not produce identical risk difference
outcomes to relapse rate differences.
Significant heterogeneity in risk difference estimates across
studies was addressed with subgroup andmeta-regression analysis.
We examined study-level characteristics (or factors), which we
identified a priori as having the potential to influence relapse
rates. These included: (a) specific trial discontinuation strategy
(i.e. total medication discontinuation [e.g. placebo] versus
graded discontinuation or intermittent treatment strategies), (b)
follow-up period (i.e. ≤1 year v. >1 year, as a proxy for short-
term and longer-term studies), (c) relapse threshold (defined as
moderate versus high threshold, using the number of measure-
ments of relapse criteria used in the studies as previously defined
by37), and (d) documented psychosocial interventions (such as
input from an early intervention team) in the treatment-as-usual
group. We also considered aspects of study design; these were:
(a) sample size (n < 40 v. n ≥ 40; a proxy for small and larger
studies), (b) trial type (open versus blinded), (c) low versus high
risk of bias, and (d) exclusion of patients with drug or alcohol
dependency.
First, we used subgroup analysis to calculate individual pooled
risk differences for each group according to study factor (e.g. a
pooled risk difference for small and large studies, respectively).
We present these subgroup risk differences graphically. The sub-
group analysis provides two statistical results. For example, when
examining the effect of trial type, we can ascertain whether the
risk difference of relapse due to maintenance versus discontinuation
medication is significant in group 1 (e.g. studies using open trials)
and group 2 (e.g. studies with blinded trials), respectively. Second,
we extended the subgroup analysis by using meta-regression to stat-
istically test whether each study factor was significantly related to
variations in risk difference across studies (i.e. whether study char-
acteristic significantly influenced the magnitude of the risk
difference).
Results
Included studies
We identified seven studies for inclusion in the review, which in
total included 520 participants. See Fig. 1 for the PRISMA flowchart
outlining the search and selection strategy. Table 1 outlines themain
characteristics of the studies included in the meta-analysis. Studies
had been published between 1982 and 2013. One study was con-
ducted in the Netherlands,31 two in Germany,9,23 two in the
UK,28,29 one in the USA27 and one in Hong Kong.30 Four studies
had a 1-year follow-up23,27,29,30 and three of the studies had a
2-year follow-up period.9,28,31
All seven studies had randomised designs: five studies
compared maintenance with complete discontinuation of medica-
tion,27–31 and two compared maintenance with intermittent, tar-
geted treatment and intermittent or rescue treatment if prodromal
symptoms occurred during the reduction.9,23 Of the five complete
discontinuation studies, four were double-blind studies with
placebo medication in the intervention group.27–30 The other
study was an open randomised trial with gradual withdrawal
(6–12 weeks) of antipsychotics.31
Intermittent or targeted treatment approaches varied slightly
across studies. Gaebel et al23 compared prodrome- and crisis-
based intermittent treatment approaches with maintenance
medication. Both intermittent interventions used a step-by-step dis-
continuation (50% every 2 weeks) of antipsychotic treatment
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Table 1 Randomised controlled studies comparing medication discontinuation with maintenance treatment for the prevention of relapse in first episode schizophrenia
Study
(location)
Number of
participants Diagnosis
Study
design
Remission
duration
Intervention
group
Control
group Relapse definition
Follow-up
duration after
discontinuation
Relapse
rate
Hospital
admission
rate
Kane et al,
198227 (USA)
28; MT = 11
PL = 17
S (RDC), unspecified
psychosis, other
psychiatric disorder,
manic disorder with
schizotypal features
RCT (double-
blind)
At least 4 weeks
stable
remission
Placebo Fluphenazine
hydrochloride (5–20
mg/day),
fluphenazine
decanoate i.m. (12.5–
50 mg every 2 weeks)
Substantial clinical
deterioration with a
potential for marked social
impairment
1 year 41 v. 0%
Crow et al,
198628 (UK)
120; MT = 54
PL = 66
Schizophrenic illness
(PSE)
RCT (double-
blind)
30 days
discharge
status
Placebo Flupenthixol i.m. (40 mg/
month),
chlorpromazine (200
mg), haloperidol (3
mg), pimozide (4 mg),
trifluoperazine (5 mg)
Readmission to psychiatric
care for any reason,
readmission considered
necessary by the clinicians
responsible but for some
reason not possible (e.g.
lack of beds, refusal of
patient), active
antipsychotic medication
considered by the clinician
to have become essential
because of features of
imminent relapse
2 years 62 v. 46% (raw
score)
McCreadie et al,
198929 (UK)
15; MT = 8
PL = 7
S (clinical) RCT (double-
blind)
1 year relapse
free on
treatment
Placebo Pimozide or flupenthixol
i.m.
Hospital admission 1 year 57 v. 0%
Gaebel et al,
200223
(Germany)
115; MT = 36
PI = 39
CI = 40;
patients who
could be
discontinued:
PI = 31
CI = 32
S (ICD-9 (1978) and RDC) RCT (open) Stable clinical
condition for
at least 3
months
Targeted
discontinuation:
• prodrome-
based
intervention
• crisis
intervention
Standard treatment (at
least 100 mg
chlorpromazine
equivalents per day)
Psychotic deterioration of
maximum intensity usually
demanding hospital
admission and minimum
change score on the BPRS
psychotic factor ≥10,
GAS ≤ 20 and CGI ≥ 6
2 years MT: 38%
PI: 42%
CI: 67%
31 v. 38%
Chen et al,
201030 (Hong
Kong)
178; MT = 89
PL = 89
S, SCP, SCA, brief
psychotic disorder
NOS (DSM-IV, 1994)
RCT (double-
blind)
1 year relapse
free on
treatment
Placebo 400 mg quetiapine Reappearance of definite
psychotic symptoms
(beyond thresholds on
PANNS subscales 3–5) and
CGI severity ≥3
1 year 63 v. 30%
(raw score)
16 v. 6%
Boonstra et al,
201131
(Netherlands)
20; MT = 9
DS = 11
S, SCP, SCA (SCID-IV) RCT (open) 1 year in
remission
Medication
discontinuation
Medication continuation
for a minimum of
6 months
≥4 any PANSS core item and
20% increase in total
PANSS or admission to
hospital
2 years 91 v. 45%
(Kaplan–
Meier)
36 v. 12%
Gaebel et al,
20119
(Germany)
44; MT = 23
DS = 21
S, SCP (clinical ICD-10,
1992)
RCT (open) 1 year relapse
free on
treatment
Targeted
discontinuation:
intermittent
treatment
Risperidone or
haloperidol
continuation (2–8 mg)
PANSS positive change >10,
CGI change ≥6 and GAF
decrease >20
1 year 19 v. 0% 19 v. 0%
MT,maintenance treatment; PL, placebo; S, schizophrenia; RDC, research diagnostic criteria; RCT, randomised controlled trial; PSE, present state examination; i.m., intramuscular; PI, prodrome based intervention; CI, crisis intervention; BPRS, brief psychiatric rating scale; GAS, global
assessment scale; CGI, clinical global impression; SCP, schizophreniform psychosis; SCA, schizoaffective psychosis; NOS, not otherwise specified; DS, discontinuation strategy; PANSS, positive and negative syndrome scale; SCID-IV, Structured Clinical Interview for DSM-IV.
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following clinical stabilisation. In the prodrome-based approach,
treatment was reintroduced if prodromal symptoms occurred. In
the crisis-based approach, treatment was reintroduced if a ‘crisis’
(i.e. full relapse) occurred. As we could only use data from the
same patient once in each meta-analyses,38 we elected to combine
data from the prodrome-based intervention. In a separate study,9
the same research group used a similar prodrome-based targeted
intermittent treatment in which the antipsychotic treatment was
completely removed over a period of 3 months. Drug treatment
was restarted if there were prodromal symptoms or early warning
signs of an impending relapse.
A planned subgroup analysis of relapse rates by the psycho-
social treatment offered in the treatment-as-usual group was not
possible due to insufficient information. The reporting of the
additional (psychosocial and other pharmacological) treatments
in the trials was variable and it was not clear if any of the
trials had specific non-pharmacological relapse prevention
strategies.
Excluded studies
The studies of Wunderink et al8,22 were not included in the final
review because they met an exclusion criteria (‘less than 50% of
the patients in the discontinuation group were able to fully discon-
tinue medication’) and were thus deemed to be closer to dose reduc-
tion studies than medication discontinuation studies. Given the
importance of these two studies (due to the long-term follow-up),
we performed a supplementary meta-analysis incorporating their
relapse results (Supplementary Figure 1 and Table 2). The overall
results with regard to relapse rates remain similar in this additional
analysis.
Quality assessment
Using the Cochrane guidelines to assess risk of bias, none of the
studies showed a low risk of bias in all seven domains (see
Supplementary Table 1 for risk of bias allocations for each study).
The mean risk of bias score for the studies was 6 out of 9.
Titles and abstracts
identiﬁed and screened
n = 2092
Duplicate n = 18 Excluded n = 1926 
Attempted to locate full
copies of articles and
assessed for eligibility
n = 148
104 excluded due to:
Conference abstracts (31)
Not in English (4)
Did not meet inclusion criteria
(69)   
Studies identiﬁed from
searching in reference
list n = 11
55 full text
articles obtained  
48 excluded due to:
No discontinuation group
(32)
Participants not in remission
prior to comparison (2)
First episode patients not a
separate group (3)
Literature review study (4)
Participants not ﬁrst episode
(5)
Less than 50% of patients
discontinued medication in
the trial (2)
Number of studies
meeting inclusion
criteria and included in
the review
n = 7
Fig. 1 PRISMA flowchart outlining the search and selection strategy.
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Meta-analysis results
Relapse rates in maintenance medication versus discontinuation
strategy
Pooled relapse rates did not vary as a function of calculation method
(Kaplan–Meier versus raw figures), thus we included both types of
estimate in our analyses. Seven studies compared relapse rates
between maintenance and discontinuation groups.9,23,27–31 There
was a significant pooled risk difference in relapse rates between main-
tenance and discontinuation groups (Fig. 2a), with higher relapse rates
in the discontinuation groups. The pooled risk difference was 0.26
(95% CIs = 0.18, 0.34; I2 = 51.2%; P = 0.056). The pooled relapse rate
for the discontinuation groups was 53% (95% CIs = 39%, 68%) and
19% (95% CIs = 0.05%, 37%) for the maintenance groups.
Rates of hospital admission in maintenance medication versus
discontinuation strategy
Five studies examined hospital admission as an outcome.9,23,27,29–31
There were significantly higher rates of readmission in the medica-
tion discontinuation group compared with the maintenance group
(Fig. 2b); the risk difference was 0.12 (95% CIs = 0.05, 0.20; P =
0.002; I2 = 59.6%; P = 0.042). The pooled hospital admission rate
for the discontinuation groups was 22% (95% CIs = 12%, 34%)
and 11% (95% CIs = 0%, 32%) for the maintenance groups.
Subgroup analysis of relapse rates according to study characteristics
The pooled risk difference was higher with total discontinuation, e.g.
placebo, compared with targeted discontinuation/intermittent treat-
ment groups. For total discontinuation the risk difference was 0.33
(95%CIs = 0.21, 0.46;P < 0.001) and the risk difference for targeted dis-
continuation/intermittent treatment was 0.13 (95% CIs =−0.02, 0.28;
P = 0.09) (see Fig. 3a). The pooled risk difference for studies with a
longer follow-up was lower than for studies with a shorter follow-up
(longer follow-up risk difference of 0.17; 95% CIs =−0.02, 0.36; P =
0.08; shorter follow-up risk difference of 0.33; 95% CIs = 0.20, 0.45; P
< 0.001). The pooled risk difference was higher for studies with lower
relapse thresholds as defined by Gleeson et al35 (risk difference of
0.36; 95%CIs = 0.25, 0.47; P < 0.001) than those with higher thresholds
(risk difference of 0.19; 95% CIs = 0.04, 0.34; P = 0.015).
Subgroup analysis of relapse rates according to study design features
Smaller studies had a higher pooled risk difference (risk difference
of 0.46; 95% CIs = 0.28, 0.63; P < 0.001) than larger studies (risk dif-
ference of 0.20; 95% CIs = 0.08, 0.31; P = 0.001) (see Fig. 3b).
Blinded studies had a higher pooled risk difference (risk difference
of 0.32; 95% CIs = 0.18, 0.46; P < 0.001) than open studies (risk dif-
ference of 0.19; 95% CIs =−0.01, 0.38; P = 0.06). Pooled risk differ-
ences were higher for studies with a higher risk of bias score (higher
risk-of-bias risk difference of 0.30; 95% CIs = 0.11, 0.58; P = 0.001;
lower risk-of-bias risk difference of 0.25; 95% CIs = 0.09, 0.42; P <
0.002). Studies not excluding patients with drug or alcohol depend-
ency had a higher pooled risk difference (risk difference of 0.32;
95% CIs = 0.17, 0.48; P < 0.001) than those excluding patients
with drug or alcohol dependency (risk difference of 0.21; 95%
CIs = 0.01, 0.40; P = 0.04).
Meta-regression according to study factors
Independent meta-regression analyses were conducted by entering
each study factor individually to test if heterogeneity was signifi-
cantly predicted by study factor (Table 2). There were no significant
effects of study factor, although the effect of sample size in the trials
was at a trend level (P = 0.07). Because none of the study factors
were significantly associated with effect size at the individual level,
multiple meta-regression analyses were not conducted.39
Narrative synthesis
Psychosocial outcomes
Of the seven studies initially included in the review, only two9,30
provided information on psychosocial outcomes. These outcomes
included: employment status, social functioning measures and
quality of life/subjective well-being.
Employment
One study examined differences in employment outcome as a func-
tion of treatment regime. Chen et al30 found little difference
between the number of patients who had lost employment at
follow-up in the maintenance (27%) and placebo (32%) groups
(x2 = 1.52, P = 0.68).
Social functioning
Gaebel et al9 investigated social functioning as a secondary
outcome. They found that patients in the maintenance treatment
group scored significantly higher than those in the intermittent
treatment group on social functioning according to the Global
Assessment of Functioning (GAF) after adjusting for social func-
tioning at baseline (maintenance treatment: mean = 79.4 v. inter-
mittent treatment: mean = 62.1; P < 0.001).
Quality of life/subjective well-being
Gaebel et al9 examined quality of life outcomes and found no signifi-
cant effect of treatment regimen.
Discussion
Summary of results
Of the seven studies included in this review, there was a greater risk
of relapse in the discontinuation groups than in the maintenance
treatment groups (risk difference of 0.26; relapse risk of 19% in
the maintenance group and 53% in the discontinuation group).
The heterogeneity between studies was at trend level for signifi-
cance. The risk difference was lower (0.12) when admission to hos-
pital was the outcome.
Subgroup analysis suggested that the pooled risk difference of
relapse between maintenance versus discontinuation studies was
lower in studies with: a longer follow-up period, a targeted or inter-
mittent discontinuation strategy as opposed to placebo only in the
discontinuation group, a higher relapse threshold, a lower risk of
bias and a larger sample size. When the statistical significance of
these differences was tested in the meta-regression analysis
(Table 2), however, group differences did not reach significance.
This may have been partly due to a lack of power.
The narrative review of functional outcomes highlighted few
differences in quality of life or functional outcomes between main-
tenance and discontinuation groups, although there were only two
studies with appropriate data and no specific conclusions could be
made. It is worth noting that in a recent long-term follow-up
study8 (excluded from the current review due to less than 50% of
participants fully discontinuing medication) FEP patients in the dis-
continuation strategy group experienced twice the functional recov-
ery rate of those in the maintenance group. The current review
highlights the importance of including these outcomes to further
explore this question, especially as recovery in terms of functional
recovery is of particular importance to patients.40
Comparison with previous studies
Our pooled relapse rates are lower (19% for maintenance group and
53% for discontinuation group) than the two extant meta-analyses.
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There are a number of possible reasons for this discrepancy. The
review of Leucht et al15 was limited to patients with schizophrenia,
included three older studies41–43 where the primary sample was not
first episode schizophrenia patients and only those who received full
medication discontinuation, e.g. placebo as opposed to including
other discontinuation strategies (graded discontinuation and tar-
geted or intermittent strategies). In our analysis, the risk difference
for studies that employed discontinuation strategies was lower (risk
difference of 0.13). The review of Zipursky et al13 used recurrence as
their primary outcome as opposed to relapse in this study.We found
in subgroup analyses that the risk difference was lower for studies
that set a higher threshold for relapse and for those that had hospital
admission as an outcome. They excluded studies with aminimum of
6 months of remission before discontinuation and it thus excluded
some of the larger studies (e.g.30) included in our review (and the
only study in an early intervention service). Furthermore, a
number of studies with particularly high relapse rates included in
their review44,45 did not meet our inclusion criteria due to not
having a comparison group. The strategy of slowly reducing medi-
cation and monitoring for relapse (and providing prodrome-based
interventions) is the standard practice in early intervention services
worldwide if patients’ medications are being discontinued.7 The
older studies in the review did not generally have rescue medication
protocols. Our results suggest that the relapse risk in these trials
might be lower than in trials where placebo is the comparison
group, and the risk difference of the two included studies was
0.13. This could be a function of the mechanism of discontinuation
(i.e. no potential for rebound psychosis), the fact that people may
still be exposed to small doses of antipsychotics if required, the dis-
continuation may be achieved over a longer timescale and there is
access to rescue medication. The De Hert et al16 meta-analysis of
patients with schizophrenia suggests that trials with intermittent
treatment strategies had three times the odds of relapse compared
with continuous treatment. Interestingly, the availability of rescue
medication was the only study characteristic explaining systematic
differences in the odds ratio for relapse between placebo versus
Increased risk in discontinuation group (risk
difference with 95% conﬁdence intervals) 
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Increased risk in discontinuation group (risk
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Fig. 2 (a) Studies reporting risk difference (comparing maintenance to discontinuation groups) for relapse. (b) Studies reporting risk difference
(comparing maintenance to discontinuation groups) for hospital admission. Relapse studies included in analysis: Boonstra et al (2011),31 Chen
et al (2010),30 Crow et al (1986),28 Gaebel et al (2002, 2011),23,9 Kane et al (1982)27 andMcCreadie et al (1989).29 Hospitalisation studies included in
analysis: Boonstra et al (2011),31 Chen et al (2010),30 Gaebel et al (2002, 2011)23,9 and McCreadie et al (1989).35 ES, Effect size
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continuous treatment across studies in their review.16 It should be
noted that this result in our study should be interpreted with
caution due to the low number of studies in this subgroup analysis
and that the same research group that included an intermittent or
prodrome-based treatment approach performed both studies.
The smaller risk difference in studies with longer follow-up
periods also needs further consideration, although the number of
participants in the subgroup analysis was small. Whether this is a
potential artefact of the quality of the studies (including dropout
rates), an influence of potential rebound psychosis after stopping
–0.2
(a)
(b)
0 0.2 0.4 0.6
Treatment:
Discontinued
Targeted
Follow-up:
≤ 1 year
> 1 year
Relapse:
Lower threshold
Higher threshold
Increased risk in discontinuation group (risk
difference with 95% conﬁdence intervals) 
–0.2 0 0.2 0.4 0.6 0.8
Sample size:
< 40 participants;
> 40 participants
Blinding:
Blinded
Not blinded
Bias:
High risk
Low risk
Alcohol/substance use:
Not excluded
Excluded
Increased risk in discontinuation group (risk
difference with 95% conﬁdence intervals) 
Fig. 3 (a) Subgroup analysis of risk difference of relapse rates according to study characteristics (treatment strategy, follow-up period and
relapse threshold). Discontinuation studies: Boonstra et al (2011) ,31 Chen et al (2010),30 Crow et al (1986),28 Kane et al (1982)27 and McCreadie
et al (1989).29 Targeted discontinuation studies: Gaebel et al (2002, 2011).23,9 Follow-up ≤1 year studies: Chen et al (2010),30 Gaebel et al (2002),23
Kane et al (1982)27 and McCreadie et al (1989).29 Follow-up >1 year studies: Boonstra et al (2011),31 Crow et al (1986)28 and Gaebel et al (2002).23
Relapse studies with lower threshold: Boonstra et al (2011),31 Chen et al (2010)30 and Kane et al (1982).27 Relapse studies with higher threshold:
Crow et al (1986),28Gaebel et al (2002, 2011)23,9 andMcCreadie et al (1989).29 (b) Subgroup analysis of risk difference of relapse rates according to
study characteristics (sample size, blinding and risk of bias). Studies with sample size of <40 participants: Boonstra et al (2011),31Kane et al
(1982)27 andMcCreadie et al (1989).29 Studies with sample size of >40 participants: Chen et al (2010),30 Crow et al (1986)28 and Gaebel et al (2002,
2011).23,9 Blinded studies: Chen et al (2010),30 Crow et al (1986),28 Kane et al (1982)27 and McCreadie et al (1989).29 Open studies: Boonstra et al
(2011)31 and Gaebel et al (2002, 2011).23,9 High risk of bias: Crow et al (1986),28 Kane et al (1982)27 and McCreadie et al (1989).29 Low risk of bias:
Boonstra et al (2011),31 Chen et al (2010)30 and Gaebel et al (2002, 2011).23,9
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medication or that the benefits of maintenance medication for pre-
venting relapse are indeed more apparent in the short term need
more research. As only one study30 was explicitly performed in an
early intervention service and had a stated inclusion of FEP patients,
it was not possible to examine if the results would be different in an
FEP sample that includes other diagnoses with potentially better
prognoses, such as brief psychotic disorder compared with a non-
affective psychosis sample, or where specific early intervention psy-
chosocial interventions were consistently employed. It is encour-
aging that studies are currently underway in this specific
population (e.g.46,47).
Strengths and limitations
Wehave conducted a comprehensive review of the literature, using a
methodologically robust strategy. However, it is important to high-
light the limitations of the review. First, the number of studies in the
review was relatively small (seven) with a relatively small number of
participants to include in the meta-regression analysis, which will
have limited power. This may explain why some of the hypothesised
subgroup differences were not significant. A benchmark of ten
studies is often suggested for the conduct of a meta-regression,38
however, numerous reviews have been conducted with fewer
studies.46 The problems associated with using a smaller number of
studies are particularly related to multivariate meta-regression,48
which we did not conduct in this study. There is a striking deficiency
in the evidence base given how important the question of medica-
tion discontinuation after remission is to clinicians and patients.11
It is also clear that these trials have a number of methodological
issues and there were some differences in results when features of
trial quality were considered. Second, given the small number of
trials reporting data on functional outcomes, we were unable to
incorporate these outcomes in our meta-analyses. As these factors
are particularly important to patients,40 this is a considerable omis-
sion in the literature and future trials should endeavour to incorpor-
ate these outcomes. Third, we combined intermittent treatment (or
the use of treatment when prodromal symptoms occurred)
approaches with trials where a placebo was used. This was done to
represent the range of current discontinuation trials and include
strategies that are common in clinical practice. Analysis indicated
that heterogeneity between the included studies was not significant,
althoughwe accept that somemay argue these trials are substantially
different. We used relapse as our primary outcome as this is most
commonly and consistently reported. However, we accept that for
new trials in this area it will be ethically difficult not to provide
interventions to individuals if there are signs of relapse, and recur-
rence may become amore accepted outcome (despite the variable sig-
nificance). Definitions of relapse that are based on hospital admission
are in our opinion too stringent and we would suggest studies use
standard rating scale thresholds to assess relapse. Alternatively, an
objective measure of recurrence that also includes functional impact
and/or distress would give a more clinically significant outcome.
We were unable to compare specific diagnostic groups, although all
but one of the studies recruited patients with first episode schizophre-
nia. There was only one included study of a broader FEP group30 and
three studies specifically excluded patients with drug or alcohol
dependency, which may limit the generalisability to standard clinical
settings. Finally, few of the studies had reliable measures of concord-
ance for those onmaintenance (or discontinuation) therapy, whichwe
know can be variable in patients with psychotic disorders.
Clinical implications
This systematic review has demonstrated a substantial risk difference
between those maintained on antipsychotic medication versus those
who discontinue their medication following remission of a first
episode of a psychotic disorder. However, this risk difference
appears a little lower than found in previous studies and meta-ana-
lyses13,14 and lower for studies with intermittent treatment strategies.
Early intervention services in the UK and worldwide generally prac-
tice gradedmedication discontinuationwith ongoing relapse preven-
tion interventions in remitted FEP patients,49 so the results of this
review may represent current clinical practice more than previous
reviews. It is also striking that the level of quality evidence with
which to inform clinicians and advise patients is relatively weak,
often does not include important outcomes such as social function-
ing and quality of life and is mostly short term; this could be part of
the reason that controversy has remained in this area.19,49,50
Although there is some research suggesting that certain patients
(such as those without a diagnosis of schizophrenia and a short dur-
ation of untreated psychosis) may be more likely to remain in remis-
sion following the first episode,2,51 it is not consistent and there is
limited research into who might be more likely to experience
symptom exacerbation following successful antipsychotic discon-
tinuation.52 Well-designed, long-term trials – particularly those tar-
geting potential ‘good prognosis’ patients, detailing the background
psychosocial or relapse prevention strategies and those including a
wide range of outcomes – would be especially helpful to the field.
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Table 2 Univariate meta-regression results indicating impact of indi-
vidual study characteristics on risk difference estimates
Predictors B
s.e.
(B) P-value
Intervention: targeted v. total discontinuationa 0.21 0.11 0.11
Follow-up period: ≤1 year v. >1 yearb −0.17 0.11 0.21
Relapse threshold: low v. highc −0.18 0.09 0.10
Trial type: blinded v. opend −0.14 0.13 0.31
Sample size: >40 v. ≥40e 0.26 0.11 0.07
Risk of bias score <6 v. ≥6f 0.04 0.15 0.77
Exclusion of patients with drug or alcohol
dependence: yes v. nog
0.12 0.13 0.40
a. Intervention: 0 = targeted; 1 = total.
b. Follow-up period: ≤1 year = 0; >1 year = 1.
c. Relapse threshold: low = 0; high = 1.
d. Trial type: blinded = 0; open = 1.
e. Sample size: >40 = 0; <40 = 1.
f. Risk of bias score: <7 = 0; ≥7 = 1.
g. All studies included: Boonstra et al (2011),31 Chen et al (2010),30 Crow et al (1986),28
Gaebel et al (2002, 2011),23,9 Kane et al (1982)27 and McCreadie et al (1989).29 Studies
excluding patients with drug/alcohol dependency: Kane et al (1982)27 and Gaebel et al
(2002, 2011).23,9
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